They also showed that inhibiting the activation of IL-16 might be an effective treatment for systemic sclerosis.[44] Purzycka-Bohdan et al have found that the serum levels of IL-16 in psoriasis patients are significantly higher than those in healthy controls. This evidence concerns the gene IL16 and systemic sclerosis.